PLX225849
GSE146402: Characterization of an Enzalutamide Resistant Primary Prostate Cancer Xenograft Derived from a Patient of West African Ancestry
- Organsim human
- Type RNASEQ
- Target gene
- Project ARCHS4
Here we report the establishment and characterization of a Prostate Cancer Patient Derived Explant (PCPDX) from a patient of West African ancestry with metastatic castration resistant disease. The following data represents gene expression in a series of mice carrying this PCPDX and undergoing different treatment courses. Mice were treated for 10 weeks with either Enzalutamide, Cisplatin, or Docetaxel, or appropriate vehicle controls. SOURCE: Jennifer Freedman (jennifer.freedman@duke.edu) - Duke Cancer Institute
View on GEOView in PlutoKey Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreAnalyze and visualize data for this experiment
Use Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView QC data and experiment metadata
View quality control data and experiment metadata for this experiment.
Request import of other GEO data
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team